This excerpt taken from the ELN 6-K filed Mar 30, 2009.
Our progress, goals and achievements are underscored by a deep commitment to creating, sustaining and growing the unique patient relevance of our therapies, science and relationships. In addition to the advancement of our products and clinical studies, this fundamental focus on patients is also evidenced by our collaborative research ventures, our patient assistance programmes, our intellectual property estate enabling the advancement of innovation, and the widespread, patient-facing outreach of our employees in the communities in which we work and live.
Alzheimers Drug Discovery Foundation (ADDF)
ADDF, a biomedical venture philanthropy, is the only public charity solely dedicated to rapidly accelerating the discovery and development of drugs to prevent, treat and cure Alzheimers disease and cognitive aging. On 16 April 2008, ADDF and Elan announced the winners of their third annual research award programme, Novel Approaches to Drug Discovery for Alzheimers Disease. Four international scientists received a total of $530,000 in grant funding.
The Parkinsons Institute and Clinical Center
In addition to our internal programmes for Parkinsons disease, we collaborate with world-class experts to expand the body of scientific knowledge around this disease. Our researchers have worked with scientists from the Parkinsons Institute and Clinical Center and have made significant progress in developing a new animal model, which could enable us to evaluate new treatment approaches.
The Michael J. Fox Foundation for Parkinsons Research
Since 2007, our efforts with the Michael J. Fox Foundation for Parkinsons Research have included a grant programme, Novel Approaches to Drug Discovery, designed to identify and fund promising projects, to help them advance more quickly from the lab to the clinic.
With a strong focus on the development of disease-modifying therapies for Parkinsons disease, Novel Approaches to Drug Discovery provides funding for projects of up to one years duration. Ideal proposals focus on efforts to develop promising biological targets into novel disease-modifying therapeutic strategies. Novel Approaches to Drug Discovery holds unique potential to provide awardees from both academic and biotech institutions with a clear opportunity for follow-on funding and collaboration for further development. We have an option for a right of first negotiation for any promising approaches or materials that arise out of this programme.
The Alzheimers Association
The Alzheimers Association is the leading voluntary U.S. health organisation in Alzheimers care, support and research, with a mission to eliminate Alzheimers disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. Our multi-faceted relationship with the Alzheimers Association includes participating in the Alzheimers Association Research Roundtable, a consortium of scientific thought-leaders working to facilitate the development and implementation of new treatments for Alzheimers disease.
Corporate Social Responsibility: Our Commitments and Goals
National Pain Foundation
The American Pain Society
Severe chronic pain is a condition that requires a community of support and education. We have ongoing patient education initiatives with the National Pain Foundation and the American Pain Society, and we are proud to support their efforts to provide reliable information and services to patients and healthcare providers.
The Alzheimers Society of Ireland
The Alzheimers Society of Ireland (ASI) provides care and support for those suffering from dementia and to their families and caregivers. Our support of ASI has encompassed a number of important fund-raising events, including the annual Tea Day national fundraising initiative, which we have supported at both a corporate and a hands-on level.
The Multiple Sclerosis Society
Multiple Sclerosis Ireland
The Crohns and Colitis Foundation of America
Elan and our employees participated in and offered significant fund-raising support to the Multiple Sclerosis Society, Multiple Sclerosis Ireland and the Crohns and Colitis Foundation of America. Last year, dozens of employees participated in awareness-raising and fund-raising events sponsored by these associations, collectively raising more than $30,000 in support of key programmes and initiatives.
Tysabri Financial Assistance Programme
We, along with our collaborator on Tysabri, Biogen Idec, provide Tysabri patients a wide range of support services and programmes to optimise access to Tysabri in the United States. We partner patients with a Financial Assistance Counselor to develop the best financial solution for accessing Tysabri therapy, helping to ensure that no patient is denied treatment based solely on financial reasons. Financial assistance programmes encompass a number of options; are tailored to address the various needs of patients, including those uninsured, privately insured, or insured through Medicare; and include a co-pay assistance programme with a low monthly cap, subject to annual enrollment and income limit qualifications.